ARTICLE | Company News
ARYx cardiovascular news
November 2, 2009 8:00 AM UTC
ARYx restructured and reduced headcount by 17 (23%) to 56 with cuts companywide to focus on out-licensing its late stage compounds, including budiodarone. The anti-arrhythmic amiodarone analog has co...